Cold Genesys

CG Oncology operates in the biopharmaceutical market, targeting patients with advanced cancers. The company primarily serves healthcare providers, oncologists, and patients who are in need of cutting-edge cancer treatments. Their business model revolves around the development and clinical testing of their proprietary therapies, with the aim of eventually bringing these treatments to market through regulatory approval and commercialization.

Revenue generation for CG Oncology is expected to come from the successful commercialization of their therapies, partnerships with larger pharmaceutical companies, and potential licensing deals. The company is led by a team of experienced professionals with backgrounds in regulatory affairs, clinical development, and international investment.